Hello, everyone, and how are you today? We hope the weekend was relaxing and refreshing. Now, though, the time has come to resume that familiar routine of meetings and deadlines and more meetings. As always, there is much to do. For instance, we are preparing to host a panel at the
DIA gathering next week. Meanwhile, though, we must tend to today. So please join us for a cup of stimulation as we dig in. Hope your day goes well and stay in touch...Germany's Biotest Becomes First Drugmaker To Exit Greece (Reuters)
Merck Bets $15M On Ambrx And 'Smart Bomb' Antibodies (Xconomy)
Onyx Cancer Drug Risks Outweigh Benefit: FDA Staff (Bloomberg News)
Merck Loses Patent Ruling Against Apotex Over Nasonex (Bloomberg News)
Roche Buys Rights To Alzheimer's Drug From AC Immune (Reuters)
Takeda To Stop Selling 13 Pfizer Drugs In Japan (Reuters)
Biotech Talent Flows Toward Boston (Boston Globe)
US DEA War On Painkiller Pill Mills Is Criticized (Reuters)
Piramal In Talks To Buy Cambridge Major Labs (Financial Express)
Researchers Urge EU Not To Cut Stem Cell Funding (Reuters)
Drugmakers Claim Irish Government Not Funding Cost Effective Meds (RTE News)
Valeant Buys Dental Specialist OraPharma (Pharma Times)
Mystery Sounds From A Merck Plant? No One Knows (The Reporter)
EDITOR'S NOTE: Please check this post for updates during the day